News

Alexander von Gabain: member of EIT governing board

Alexander von Gabain: member of EIT governing board

>> Official appointment of the EIT Governing Board: the European…

Promising new approach to cancer therapy

The research platform Translational Cancer Therapy Research, which was recently established by the Bernhard Keppler and…

Infection of Streptococcus: Unkown receptor molecule responsible for immune response?

Cells of the human immune system recognize the bacterium Streptococcus pyogenes differently from what has been assumed…

Affiris: Milestone reached in clinical trial of Alzheimer's vaccine

Vienna (Austria), 16. July 2008. In the clinical phase I trial AFF001,

AFFiRiS GmbH has now recruited the 24 Alzheimer…

Iomai Acquisition granted clearance by US Authorities

Iomai Acquisition granted clearance by US Authorities

» Definitive proxy statement filed on July 10, 2008; Closing…

Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU

Vienna (Austria), July 09, 2008 – Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal…

Nabriva Therapeutics Announces Appointment of New CEO

Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed…

The Centre of Innovation & Technology of the City of Vienna supports 7-Tesla project at MUV/General Hospita...

The Centre of Innovation & Technology of the City of Vienna supports 7-Tesla project at MUV/General Hospital of Vienna…

Best of Biotech business plan - the winners

Best of Biotech business plan

- the winners

>> New antibiotic from Graz most impresses the jury

Earlybird Venture Capital leads Investiment in Miracor

Earlybird announces the completion of a Series A financing round of € 6 million in Miracor GmbH based in Vienna. Miracor…

Sanochemia: US patent granted for the formulation and use of the active pharmaceutical ingredient PVP hyper...

Sanochemia: US patent granted for the formulation and use of the active pharmaceutical ingredient PVP hypericin

Intercell - Licensure application for Japanese Encephalitis vaccine submitted to Canadian Division of Biolo...

Intercell - Licensure application for Japanese Encephalitis vaccine submitted to Canadian Division of Biologics and…

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.